Evaluation of Risk Factors for Rectus Sheath Hematoma

Clin Appl Thromb Hemost. 2016 Apr;22(3):292-6. doi: 10.1177/1076029614553024. Epub 2014 Oct 7.

Abstract

Rectus sheath hematoma (RSH) develops due to rupture of epigastric arteries or the rectus muscle. Although RSH incidence rate is low, it poses a significant diagnostic dilemma. We evaluated the risk factors for RSH, its presentation, management, and outcomes for 115 patients hospitalized with confirmed RSH by computed tomography scan between January 2005 and June 2009. More than three-fourth (77.4%) of the patients were on anticoagulation therapy, 58.3% patients had chronic kidney disease (CKD) stage ≥3, 51.3% had abdominal injections, 41.7% were on steroids/immunosuppressant therapy, 37.4% had abdominal surgery/trauma, 33.9% had cough, femoral puncture was performed in 31.3% of patients, and 29.5% were on antiplatelet therapy. Rectus sheath hematoma was not an attributable cause in any of the 17 deaths. Mortality was significantly higher in patients with CKD stage ≥3 (P = .03) or who required transfusion (P = .007). Better understanding of RSH risk factors will facilitate early diagnoses and improve management.

Keywords: anticoagulants; bleeding; heparins; renal failure.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged, 80 and over
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Epigastric Arteries / diagnostic imaging*
  • Female
  • Hematoma* / diagnostic imaging
  • Hematoma* / etiology
  • Hematoma* / mortality
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects
  • Rectus Abdominis / diagnostic imaging*
  • Retrospective Studies
  • Risk Factors
  • Tomography, X-Ray Computed*
  • Wounds and Injuries / complications
  • Wounds and Injuries / diagnostic imaging
  • Wounds and Injuries / mortality

Substances

  • Anticoagulants
  • Immunosuppressive Agents
  • Platelet Aggregation Inhibitors